The present invention provides bispecific antibodies that bind to CD3 and tumor antigens and methods of using the same. According to certain embodiments, the bispecific antibodies of the invention exhibit reduced 
effector functions and have a unique binding profile with regard to Fcγ receptors. The bispecific antibodies are engineered to efficiently induce 
T cell-mediated killing of 
tumor cells. According to certain embodiments, the present invention provides bispecific 
antigen-binding molecules comprising a first 
antigen-
binding domain that specifically binds human CD3, a second 
antigen-binding molecule that specifically binds human CD20, and an 
Fc domain that binds Fcγ receptors with a specific 
binding pattern. In certain embodiments, the bispecific antigen-binding molecules of the present invention are capable of inhibiting the growth of B-
cell or 
melanoma tumors expressing CD20. The bispecific antibodies of the invention are useful for the treatment of various cancers as well as other CD20-related diseases and disorders.